{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=68&state=Colorado",
    "query": {
      "state": "Colorado",
      "city": "Denver",
      "page": 68
    },
    "page_size": 10
  },
  "pagination": {
    "page": 68,
    "page_size": 10,
    "total_count": 7459,
    "total_pages": 746,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=69&state=Colorado&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Denver&page=67&state=Colorado&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T16:53:48.610Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02520245",
      "title": "Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "REGN2810",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-08",
      "completion_date": "2023-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-07",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Denver, Colorado • St Louis, Missouri + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02520245"
    },
    {
      "nct_id": "NCT02064439",
      "title": "Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Embolism",
        "Thromboembolism",
        "Thrombosis",
        "Venous Thrombosis",
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "BAY 59-7939",
          "type": "DRUG"
        },
        {
          "name": "ASA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3365,
      "start_date": "2014-03-05",
      "completion_date": "2016-11-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-19",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 24,
      "location_summary": "Beverly Hills, California • La Jolla, California • Ventura, California + 19 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02064439"
    },
    {
      "nct_id": "NCT00380939",
      "title": "This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Arteriosclerosis"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Pravastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "30 Years to 75 Years"
      },
      "enrollment_count": 600,
      "start_date": "1999-04",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2006-12-04",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 36,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 30 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00380939"
    },
    {
      "nct_id": "NCT01502319",
      "title": "Military Suicide Research Consortium",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Suicidal and Self-injurious Behaviour"
      ],
      "interventions": [
        {
          "name": "Cognitive therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Eastern Colorado Health Care System",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 5400,
      "start_date": "2010-09",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2017-10-20",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502319"
    },
    {
      "nct_id": "NCT01467505",
      "title": "An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Immunosuppressant Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 61,
      "start_date": "2012-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-06-18",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01467505"
    },
    {
      "nct_id": "NCT03499353",
      "title": "Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Early Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TALAZOPARIB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2018-08-27",
      "completion_date": "2020-09-23",
      "has_results": true,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 97,
      "location_summary": "Gilbert, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 64 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Camarillo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499353"
    },
    {
      "nct_id": "NCT06046222",
      "title": "Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Eosinophilic Granulomatosis With Polyangiitis",
        "Churg-Strauss Syndrome"
      ],
      "interventions": [
        {
          "name": "NS-229",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2023-12-20",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 7,
      "location_summary": "Denver, Colorado • Rochester, Minnesota • Cleveland, Ohio + 4 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06046222"
    },
    {
      "nct_id": "NCT06001788",
      "title": "Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML",
        "AML With Mutated NPM1",
        "Hematologic Malignancy",
        "KMT2Ar",
        "NPM1 Mutation",
        "MLL Rearrangement",
        "Leukemia",
        "Acute Myeloid Leukemia",
        "Leukemia, Myeloid",
        "Leukemia, Myeloid, Acute",
        "Acute Leukemia",
        "Neoplasms by Histologic Type"
      ],
      "interventions": [
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony-stimulating factor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Kura Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2024-02-22",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 38,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Orange, California + 32 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06001788"
    },
    {
      "nct_id": "NCT04320069",
      "title": "Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Omnipod Horizon™ Automated Glucose Control System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Insulet Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "2 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2020-06-09",
      "completion_date": "2020-09-29",
      "has_results": true,
      "last_update_posted_date": "2023-11-13",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 4,
      "location_summary": "Santa Barbara, California • Denver, Colorado • Atlanta, Georgia + 1 more",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04320069"
    },
    {
      "nct_id": "NCT05058651",
      "title": "Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Advanced Extrapulmonary Neuroendocrine Carcinoma",
        "Metastatic Extrapulmonary Neuroendocrine Carcinoma",
        "Recurrent Extrapulmonary Neuroendocrine Carcinoma",
        "Unresectable Extrapulmonary Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 189,
      "start_date": "2022-06-28",
      "completion_date": "2028-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-15T16:53:48.610Z",
      "location_count": 266,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 200 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05058651"
    }
  ]
}